Insights from AAD VMX 2020
Researchers found that daxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin in development, is safe with high response rat
Kristian Reich, MD, PhD, discusses the results of two phase 3 clinical trials, BE-READY and BE-VIVID, that tested the efficacy and safety of bimekizumab, a novel IL-17A/IL-17F inhibitor.
Bruce M. Katz, MD, discusses the results of two phase 3 clinical trials on daxibotulinumtoxinA for injection, the development of a onabotulinumtoxinA biosimilar, and the current state and future of cosmetic dermatology practice.
A recent poster abstract investigated the impact of insurance type, such as private or Medicaid, on delay in diagnosis among patients with hidradenitis suppurativa.
Findings from a recent study found hair coverage and visibility of the scalp may be factors in the detection of melanomas on the scalp.
Findings from a recent poster abstract highlight the potential association between cumulative steroid use and diabetes risk.
In a small study, researchers assessed the safety and efficacy of ustekinumab intravenous induction among patients with severe hidradenitis suppurativa.
While the “ABCD” acronym (Asymmetry, Border, Color, Diameter) was developed more than 35 years ago, modern clinicians may wonder if its
A recent study found that patients had the highest overall treatment satisfaction with anti-IL-17 class therapies. The poster, presente
Findings from a recent poster abstract presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for abrocitinib, an oral Janus kinase inhibitor.
Stay in the know.
The Dermatologist Newsletter
The Dermatologist Newsletter
Back to Top